WinSanTor has a drug in FDA trials that shows significant promise in combating neuropathy. Neuropathy causes debilitating loss of feeling, particularly in digits that can impede simple function and even walking. It’s generally caused by diabetes, chemotherapy, or nervous system disease. This is a significant global market opportunity without similar competing compounds. The drug has been in use in western countries for 30 years which should be helpful to its approval process. In addition, WinSanTor has transitioned this compound from tablet form to topical. This reformulation may be an additional opportunity for the company for other ingestible tablets that may be converted to topical use.